The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
Market view
pembrolizumab · Liquid
2 marketed package NDCs · 2 active manufacturers
Same drug class
Other molecules FDA puts in Programmed Death Receptor-1 Blocking Antibody, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- atezolizumab and hyaluronidase-tqjs· 1 maker
- nivolumab and hyaluronidase-nvhy· 1 maker
- nivolumab and relatlimab-rmbw· 1 maker
- pembrolizumab and berahyaluronidase alfa-pmph· 1 maker
- retifanlimab-dlwr· 1 maker
- toripalimab-tpzi· 1 maker
- atezolizumab· 2 makers
- dostarlimab· 2 makers
- tislelizumab-jsgr· 2 makers
- nivolumab· 6 makers
Common questions
- Is Pembrolizumab in shortage right now?
- No. FDA does not currently list Pembrolizumab in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Pembrolizumab?
- 5 companies have marketed Pembrolizumab in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.